To investigate the role of EGFR in PLOD2-induced ccRCC progression, Gefitinib, a specific inhibitor of EGFR, was administered to PLOD2-overexpressed ccRCC cells to monitor the changes in cellular proliferation and migration. This evidence concerns the gene PLOD2 and nonpapillary renal cell carcinoma.